Chi

Research Analyst at Bank of America Corp. /de/

Chi Fong is an analyst at Bank of America specializing in financial sector research, but publicly available records provide limited detail on their company coverage, performance metrics, or specific industry achievements. There is no documentation of notable ranking, investment return data, or individual success rates accessible through professional investment or analyst tracking platforms. Chi's earlier career history, previous roles, and the date they joined Bank of America remain undisclosed within current records. Likewise, information regarding securities licenses, FINRA registration, and industry credentials could not be corroborated from publicly verifiable sources.

Chi's questions to GALAPAGOS (GLPG) leadership

Question · Q1 2024

May 3, 2024

Asked two questions about the immunology pipeline: one on the R&D strategy for CAR-T in autoimmune diseases beyond lupus, and another on the potential for expanding the TYK2 inhibitor (3667) into new indications like uveitis.

Answer

For the TYK2 inhibitor, the company is focused on delivering proof-of-concept results in lupus and dermatomyositis before considering expansion into other indications. For autoimmune CAR-T, they are actively exploring new non-viral vector technologies through internal R&D and external collaborations.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies

Access millions of SEC filings & transcripts

Get answers cited to the source

Try Fintool for Free

Trusted by leading investment firms and analysts